Adjuvant immunotherapy in the modern management of resectable melanoma: current status and outlook to 2028
Looking ahead to 2028, adjuvant immunotherapy will remain a key option of comprehensive melanoma care, particularly for patients with stage IIB/C and stage III with micrometastatic disease, where neoadjuvant immunotherapy is not feasible.
Authors
- Paweł Sobczuk (ORCID: https://orcid.org/0000-0002-4103-1626)
- Ivan Pourmir (ORCID: https://orcid.org/0000-0002-4946-1719)
- Gabriella Liszkay (ORCID: https://orcid.org/0000-0001-6161-2033)
- A. Zhukavets
- Marco Donia (ORCID: https://orcid.org/0000-0003-4966-9752)
- Mathilde Jalving (ORCID: https://orcid.org/0000-0002-9142-9050)
- Eva Ellebæk (ORCID: https://orcid.org/0000-0001-6748-9232)
- Hildur Helgadóttir (ORCID: https://orcid.org/0000-0002-0735-4771)
- Christoph Höeller (ORCID: https://orcid.org/0000-0003-1192-0227)
- Teresa Amaral (ORCID: https://orcid.org/0000-0002-2516-5181)
- I. Gavrilova
- Hans M. Westgeest (ORCID: https://orcid.org/0000-0002-5735-3638)
- Iván Márquez‐Rodas (ORCID: https://orcid.org/0000-0002-2476-668X)
- Dace Pjanova (ORCID: https://orcid.org/0000-0002-3993-7939)
- Micaela Hernberg (ORCID: https://orcid.org/0000-0002-0139-4596)
- Bart Neyns (ORCID: https://orcid.org/0000-0003-0658-5903)
- Hanna Eriksson (ORCID: https://orcid.org/0000-0001-6728-5344)
- Henrik Jespersen (ORCID: https://orcid.org/0000-0002-6543-5369)
- Rebecca Lee (ORCID: https://orcid.org/0000-0003-2540-2009)
- Lidija Kandolf
Institutions
- Oslo University Hospital (NO)
- Military Medical Academy (RS)
- University Medical Center Groningen (NL)
- Karolinska University Hospital (SE)
- University of Helsinki (FI)
- Inserm (FR)
- Helsinki University Hospital (FI)
- Herlev Hospital (DK)
- Copenhagen University Hospital (DK)
- Karolinska Institutet (SE)
- Hospital General Universitario Gregorio Marañón (ES)
- Manchester University NHS Foundation Trust (GB)
- Hôpital Européen Georges-Pompidou (FR)
- Amphia Ziekenhuis (NL)
- University Specialized Hospital for Active Treatment of Endocrinology (BG)
- National Institute of Oncology (HU)
- Riga Stradiņš University (LV)
- Universitair Ziekenhuis Brussel (BE)
- The Christie NHS Foundation Trust (GB)
- Belarusian State Medical University (BY)
- Medical University of Vienna (AT)
- University of Tübingen (DE)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-02-15
- DOI
- https://doi.org/10.1016/j.esmoop.2025.104295
- Citations
- 8
- Primary Topic
- Cutaneous Melanoma Detection and Management
- Type
- article
- Field-Weighted Citation Impact
- 8.36
Funders
- Amgen
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- American Society of Clinical Oncology
- Regeneron Pharmaceuticals
- Wellcome Trust
- Les Laboratories Pierre Fabre
- Universität Wien
- Novo Nordisk
- Medizinische Universität Wien
- Sun Pharma
- Unicancer
- NeraCare